A widely used opioid-acetaminophen combination product, oxycodone/APAP 7.5-325mg and 10-325mg, has seen a significant drop in price! This will dramatically mitigate the Part D allocation

Holding true to the suspicion that a new User Guide is released during a holiday, CMS recently published version 5.6 of the NGHP User Guide. 

Provigil® (modafinil) is a wakefulness-promoting agent, which is FDA approved for excessive somnolence associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. It

Medicare Advantage organizations (MAOs) earned another small victory with a favorable ruling on a motion to dismiss out of Federal Court in Boston. The case, MSP

Lyrica® (pregabalin) is at last available generically through manufacturer/distributor, Rising Pharmaceuticals! The exclusive patent was extended for six months when Lyrica® was approved for pediatric

Flector® (diclofenac epolamine) 1.3% topical patch is a nonsteroidal anti-inflammatory drug (NSAID) which is FDA indicated for acute pain due to minor strains, sprains and contusions. As

Medicare Advantage plans have, in many areas, moved aggressively to wield the Medicare Secondary Payer “private cause of action” and obtain reimbursement for payments that

Standard operating procedure when settling a personal injury claim: parties should first determine if a plaintiff is a Medicare beneficiary, and once confirmed  should comply with

The Centers for Medicare & Medicaid Services (CMS) hosted a webinar on March 13th for users regarding upcoming enhancements to the Medicare Secondary Payment Recovery Portal